Coloplast in the news
Developing intimate healthcare solutions
Tamtam found 20 recent articles about Coloplast.
- Union says Coloplast layoffs hit broadly across company
Coloplast enacted widespread layoffs, with a union agreement providing fair terms for affected staff.
- What Coloplast (CPSE:COLO B)'s Earnings And Guidance Mean For Shareholders
Coloplast reported mixed full-year results with lower net income, but is forecasting 7% to 9% revenue growth for 2026/27, aiming to rebuild earnings momentum.
- Shareholder slams Coloplast pay report: “To put it mildly, it’s completely unacceptable”
Shareholders are criticizing Coloplast's executive pay report, particularly concerning sign-on bonuses.
- Coloplast stock faces lower 2030 growth target after guidance reset
Coloplast revised its long-term financial ambitions downwards, targeting 5%-7% annual organic revenue growth through 2030 due to market challenges and increased investments.
- Coloplast leaves room for a large sign-on bonus for its new CEO but won’t disclose the full amount
Coloplast's new CEO is receiving a sign-on bonus, part of which is tied to the company's share price, with the full amount undisclosed.
- Coloplast: Turnaround Is Underway, But Upside Is Limited (OTCMKTS:CLPBF)
Coloplast's turnaround is underway, but upside is limited, with revised guidance, impairment, and growth in EPS and free cash flow, alongside key market risks.
- DNB Carnegie raises target price for Coloplast to DKK 540 (520), reiterates hold
DNB Carnegie increased Coloplast's target price to DKK 540 from DKK 520, maintaining a hold rating.
- Weekly Recap: Revenue growth with EBIT decline and China recovery delay
Coloplast achieved 6% organic revenue growth in FY 2025/26 despite a 3% EBIT decline, while projecting 5–7% organic growth for the next year and delaying China business stabilization until 2027/28.
- Coloplast nominates Lundbeck CEO to its board
Coloplast intends to expand its board and has nominated Lundbeck's CEO to join it.
- Coloplast A/S 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:CLPBY) 2026-11-07
Coloplast A/S released its Q4 2026 earnings call presentation, detailing the company's financial results for the period.
- Coloplast down 4% as UBS sees limited upside after guidance cut
Coloplast's shares fell over 4% after UBS downgraded the stock to "neutral" due to revised growth and margin targets, indicating limited future upside.
- Key facts: Coloplast Q4 profit up 36%; plans DKK 500m savings
Coloplast's Q4 revenue grew 7% and net profit increased 36%, with plans to save DKK 500 million through various operational adjustments.
- Coloplast Publishes Q4 2026 Earnings Call Transcript
Coloplast updated its 2030 financial targets, aiming for 5-7% annual organic growth and a mid-20s EBIT margin, while also forecasting 5-7% organic growth and about 25% EBIT margin for fiscal 2026/2027.
- Barclays upgrades Coloplast stock rating on growth outlook By Investing.com
Barclays upgraded Coloplast's stock rating to Overweight, expecting accelerated growth and increased margins by 2030, while other institutions have varied assessments of the company's future performance.
- Coloplast (CPSE:COLO B) FY Results Clash With Kerecis Impairment
Coloplast's strong organic revenue growth and EBIT margin were overshadowed by a DKK3.2 billion impairment related to Kerecis, impacting reported profit and delaying its expected contribution to earnings.
- Coloplast savings plan has cost at least 80 jobs, more layoffs possible
Coloplast's savings plan has led to at least 80 job cuts in its China and wound care businesses, with potential for further reductions.
- Coloplast stock falls on EBIT miss, revised outlook
Coloplast's stock fell after its Q4 earnings missed profit expectations and it revised its outlook for fiscal 2026/27, despite strong organic revenue growth.
- Coloplast Sees FY 2026/27 EBIT Margin At Around 25%
Coloplast projects an EBIT margin of around 25% for the fiscal year 2026/27.
- Why is Coloplast stock declining today? By Investing.com
Coloplast's stock declined 2.3% today due to lower-than-expected Q4 EBIT, a contracted EBIT margin, conservative future guidance, and revised long-term growth targets, leading to analyst price target reductions.
- Coloplast A/S - Annual Report 2025/26 & Remuneration Report 2025/26
Coloplast achieved 6% organic growth and a 26% EBIT margin in FY 2025/26, with a positive outlook for continued growth and profitability towards 2030 despite inflationary pressures.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Coloplast?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies